

Zhen-Yu Ding

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6962902/publications.pdf>

Version: 2024-02-01

73
papers

3,831
citations

471509

17
h-index

138484

58
g-index

78
all docs

78
docs citations

78
times ranked

5324
citing authors

#	ARTICLE	IF	CITATIONS
1	The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis. <i>Head and Neck</i> , 2022, 44, 518-529.	2.0	5
2	Editorial: The Clinical Application of Neoantigens. <i>Frontiers in Immunology</i> , 2022, 13, 842633.	4.8	0
3	Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient. <i>Frontiers in Pharmacology</i> , 2022, 13, 817265.	3.5	5
4	Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 1153-1164.	1.9	5
5	Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer. <i>Disease Markers</i> , 2022, 2022, 1-11.	1.3	16
6	Identifying tumor antigens and immunosubtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine. <i>Cancer Medicine</i> , 2022, , .	2.8	3
7	Linkage of time interval from neoadjuvant chemoradiotherapy to surgery with pathological response and survival profile in resectable esophageal cancer patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16071-e16071.	1.6	0
8	Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. <i>International Immunopharmacology</i> , 2021, 91, 107296.	3.8	20
9	Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report. <i>Thoracic Cancer</i> , 2021, 12, 1234-1239.	1.9	3
10	Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1073-1081.	2.0	13
11	Inhibition of FGF/FGFR and VEGF/VEGFR signalling in cancer treatment. <i>Cell Proliferation</i> , 2021, 54, e13009.	5.3	76
12	Toxicities of Immunotherapy for Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 603658.	2.8	6
13	Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors. <i>Journal of Bone Oncology</i> , 2021, 29, 100369.	2.4	5
14	Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy. <i>Lung Cancer</i> , 2021, 160, 50-58.	2.0	14
15	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 100, 108128.	3.8	13
16	Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 26.	17.1	112
17	Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma. , 2021, 9, e002836.		31
18	Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma. <i>Disease Markers</i> , 2021, 2021, 5340240.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma. <i>Disease Markers</i> , 2021, 2021, 1-18.	1.3	13
20	A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. <i>Investigational New Drugs</i> , 2020, 38, 478-484.	2.6	5
21	Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 135-145.	4.2	42
22	<p>Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11761-11772.	1.9	1
23	The Ways of Isolating Neoantigen-Specific T Cells. <i>Frontiers in Oncology</i> , 2020, 10, 1347.	2.8	19
24	Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome. <i>BioMed Research International</i> , 2020, 2020, 1-16.	1.9	11
25	Crizotinib versus chemotherapy: a real-world costâ€ effectiveness study in China. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 93-102.	1.4	7
26	Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. <i>Nature Medicine</i> , 2020, 26, 732-740.	30.7	322
27	Anlotinibâ€ induced acute myocardial infarction: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 3203-3207.	1.8	3
28	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. <i>Molecular Biomedicine</i> , 2020, 1, 16.	4.4	4
29	Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 1184.	3.5	50
30	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	13.7	2,347
31	PD-1 Inhibitors in the Advanced Esophageal Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 1418.	3.5	22
32	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	3.5	75
33	A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 321-328.	1.5	61
34	Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and doseâ€ volume histogram parameters. <i>Radiotherapy and Oncology</i> , 2019, 132, 197-203.	0.6	33
35	Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20674-e20674.	1.6	1
36	Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report. <i>Annals of Translational Medicine</i> , 2019, 7, 149-149.	1.7	4

#	ARTICLE	IF	CITATIONS
37	Monitoring the estimated glomerular filtration rate (eGFR) in patients with small-cell lung cancer during chemotherapy: equations based on serum creatinine or cystatin C?. <i>International Journal of Clinical Oncology</i> , 2018, 23, 258-265.	2.2	2
38	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 816-824.	1.4	9
39	Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 421-426.	1.0	3
40	Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report. <i>Thoracic Cancer</i> , 2018, 9, 1190-1193.	1.9	13
41	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. <i>Oncology Letters</i> , 2018, 15, 5671-5679.	1.8	4
42	Association of the independent polymorphisms in CDKN2A with susceptibility of acute lymphoblastic leukemia. <i>Bioscience Reports</i> , 2018, 38, .	2.4	10
43	A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3050-3050.	1.6	17
44	Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) impact on immune microenvironment in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e21154-e21154.	1.6	2
45	Neoantigen-based personalized, immune cell therapy for patients with advanced NSCLC: A pilot study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15043-e15043.	1.6	0
46	Bone metastasis from lung cancer identified by genetic profiling. <i>Oncology Letters</i> , 2017, 13, 847-850.	1.8	4
47	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. <i>Oncotarget</i> , 2017, 8, 49680-49688.	1.8	17
48	Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score. <i>Oncotarget</i> , 2017, 8, 111309-111317.	1.8	22
49	How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation? A bicenter research and pooled analysis of published reports.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20571-e20571.	1.6	0
50	Neutrophil-Lymphocyte Ratio as a Prognostic Marker for Chemotherapy in Advanced Lung Cancer. <i>International Journal of Biological Markers</i> , 2016, 31, 395-401.	1.8	22
51	Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study. <i>Lung Cancer</i> , 2016, 96, 93-100.	2.0	32
52	Chemotherapy-induced fatal hepatitis B virus reactivation in a small-cell lung cancer patient. <i>Molecular and Clinical Oncology</i> , 2016, 5, 382-384.	1.0	7
53	Early CT perfusion changes and the outcome of antiangiogenic therapy and chemotherapy in patients with advanced primary lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20543-e20543.	1.6	1
54	Relationship of RRM1 compared to ERCC1 gene in peripheral blood to the efficacy of the gemcitabine chemotherapy in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23092-e23092.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Clinical characteristics of the mixed form of neuroendocrine tumor in the lung: A retrospective study in 2501 lung cancer cases. <i>Thoracic Cancer</i> , 2015, 6, 25-30.	1.9	11
56	Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis. <i>Molecular and Clinical Oncology</i> , 2015, 3, 633-638.	1.0	10
57	Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report. <i>Oncology Letters</i> , 2015, 9, 2874-2878.	1.8	1
58	Special AT-rich sequence binding protein 1 expression correlates with response to preoperative radiotherapy and clinical outcome in rectal cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 1738-1745.	3.4	16
59	Livin modulates the apoptotic effects of vesicular stomatitis virus in lung adenocarcinoma. <i>International Journal of Oncology</i> , 2015, 47, 1775-1782.	3.3	2
60	Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 36.	2.6	7
61	Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine. <i>Scientific Reports</i> , 2015, 5, 11275.	3.3	13
62	Orthotopic Transplantation of Cryopreserved Mouse Ovaries and Gonadotrophin Releasing Hormone Analogues in the Restoration of Function following Chemotherapy-Induced Ovarian Damage. <i>PLoS ONE</i> , 2015, 10, e0120736.	2.5	4
63	Prognostic significance of protein kinase BAKT pathway in adult adrenocortical carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22229-e22229.	1.6	0
64	Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2014, 7, 260-266.	1.8	16
65	Synthesis and biological evaluation of 4-(1,2,3-triazol-1-yl)coumarin derivatives as potential antitumor agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 799-807.	2.2	126
66	Exploring the binding mode of HIV-1 Vif inhibitors by blind docking, molecular dynamics and MM/GBSA. <i>RSC Advances</i> , 2013, 3, 22532.	3.6	11
67	Exploring the selectivity of PI3K \pm and mTOR inhibitors by 3D-QSAR, molecular dynamics simulations and MM/GBSA binding free energy decomposition. <i>MedChemComm</i> , 2013, 4, 1482.	3.4	9
68	Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multicenter prospective study. <i>Thoracic Cancer</i> , 2013, 4, 14-19.	1.9	4
69	Phase II study of oral etoposide maintenance for patients with extensive stage small cell lung cancer who have responded to the induction on an EP regimen. <i>Thoracic Cancer</i> , 2013, 4, 234-240.	1.9	5
70	Clinical characteristics of mixed neuroendocrine cancer of lung: Retrospective analysis of 20 cases from 2,501 lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19055-e19055.	1.6	0
71	Cancer Microenvironment and Cancer Vaccine. <i>Cancer Microenvironment</i> , 2012, 5, 333-344.	3.1	18
72	Enantioselective Allylic Amination of Morita-Baylis-Hillman Carbonates Catalysed by Modified Cinchona Alkaloids. <i>European Journal of Organic Chemistry</i> , 2009, 2009, 5804-5809.	2.4	50

#	ARTICLE	IF	CITATIONS
73	Therapeutic vaccine for melanoma: the untouched grail?. <i>Expert Review of Vaccines</i> , 2007, 6, 907-911.	4.4	8